Comparative Pharmacology
Head-to-head clinical analysis: BETAPACE AF versus ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAPACE AF versus ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER.
BETAPACE AF vs ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sotalol is a class III antiarrhythmic agent that also has non-cardioselective beta-adrenergic receptor blocking activity. It prolongs the cardiac action potential duration by blocking potassium channels (IKr), thereby prolonging the QT interval and refractory periods.
Selective beta-1 adrenergic receptor antagonist with rapid onset and short duration of action; reduces heart rate, myocardial contractility, and blood pressure; no intrinsic sympathomimetic activity or membrane stabilizing activity.
80 mg orally twice daily. For atrial fibrillation/flutter, initiate at 80 mg twice daily; may increase after 2-3 days to 120 mg twice daily if needed. Maximum 120 mg twice daily.
Intravenous loading dose: 500 mcg/kg over 1 minute, followed by maintenance infusion: 50 mcg/kg/min for 4 minutes; if adequate response not achieved, repeat loading dose and increase maintenance infusion by 50 mcg/kg/min increments up to 200 mcg/kg/min.
None Documented
None Documented
Terminal elimination half-life: 12 hours (range 10–20 hours) in patients with normal renal function; prolonged in renal impairment (up to 42 hours in severe impairment).
Terminal elimination half-life is approximately 9 minutes (range 6–12 min) in healthy adults; prolonged to 15–20 min in hepatic impairment. Clinical context: rapid offset allows precise titration.
Primarily renal (unchanged drug and metabolites); approximately 40% excreted as unchanged sotalol in urine, with additional metabolites via fecal route (~10%). Biliary excretion minimal (<5%).
Rapid hydrolysis by esterases in blood and tissues to inactive acid metabolite (ASL-8123) and methanol. Less than 2% excreted unchanged in urine. Renal elimination of metabolite accounts for >80% of dose; <5% fecal.
Category C
Category A/B
Beta-Blocker
Beta-Blocker